Deciphering the chemical instability of sphaeropsidin A under physiological conditions - degradation studies and structural elucidation of the major metabolite.
Article in Organic & biomolecular chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Alet E van der WesthuyzenDepartment of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa. wvo@sun.ac.za.
Aude IngelsDepartment of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. Veronique.Mathieu@ulb.be and ULB Cancer Research Center, Université libre de Bruxelles (ULB), 1050 Bruxelles, Belgium.
Rémi RosièreDepartment of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. Veronique.Mathieu@ulb.be.ORCID 0000-0001-9709-0628
Karim AmighiDepartment of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. Veronique.Mathieu@ulb.be.
Lukas ObererNovartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland.ORCID 0000-0002-2654-5709
Kirk R GustafsonMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, USA.ORCID 0000-0001-6821-4943
Dongdong WangMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, USA.ORCID 0000-0002-7824-2507
Antonio EvidenteDepartment of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy.ORCID 0000-0001-9110-1656
Lucia MaddauDepartment of Agriculture, Section of Plant Pathology and Entomology, University of Sassari, Viale Italia 39, 07100, Sassari, Italy.ORCID 0000-0002-8158-8242
Marco MasiDepartment of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy.ORCID 0000-0003-0609-8902
André de VilliersDepartment of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa. wvo@sun.ac.za.ORCID 0000-0001-6212-1439
Ivan R GreenDepartment of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa. wvo@sun.ac.za.ORCID 0000-0002-9158-670X
Walter BergerDepartment of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-0014-1658
Alexander KornienkoDepartment of Chemistry and Biochemistry, Texas State University, San Marcos, Texas 78666, USA.ORCID 0000-0003-2041-7367
Veronique MathieuDepartment of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. Veronique.Mathieu@ulb.be and ULB Cancer Research Center, Université libre de Bruxelles (ULB), 1050 Bruxelles, Belgium.
Willem A L van OtterloDepartment of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa. wvo@sun.ac.za.ORCID 0000-0002-3300-6463
Funding
Acid-Sensitive Glioblastoma Prodrugs Derived from Ophiobolin AR15CA227680 · NCI · TEXAS STATE UNIVERSITY · PI KORNIENKO, ALEXANDER · 2019 to 2019
$462k
Tandem Discovery of Drug Leads and Targets via Paal-Knorr reactionR21GM131717 · NIGMS · TEXAS STATE UNIVERSITY · PI KORNIENKO, ALEXANDER, LA CLAIR, JAMES J · 2019 to 2020
The fungal metabolite sphaeropsidin A (SphA) has been recognised for its promising cytotoxicity, particularly towards apoptosis- and multidrug-resistant cancers. Owing to its intriguing activity, the development of SphA as a potential anticancer agent has been pursued. However, this endeavour is compromised since SphA exhibits poor physicochemical stability under physiological conditions. Herein, SphA's instability in biological media was explored utilizing LC-MS. Notably, the degradation tendency was found to be markedly enhanced in the presence of amino acids in the cell medium utilized. Furthermore, the study investigated the presence of degradation adducts, including the identification, isolation and structural elucidation of a major degradation metabolite, (4R)-4,4',4'-trimethyl-3'-oxo-4-vinyl-4',5',6',7'-tetrahydro-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-2-ene-2-carboxylic acid. Considering the reduced cytotoxic potency of aged SphA solutions, as well as that of the isolated degradation metabolite, the reported antiproliferative activity has been attributed primarily to the parent compound (SphA) and not its degradation species. The fact that SphA continues to exhibit remarkable bioactivity, despite being susceptible to degradation, motivates future research efforts to address the challenges associated with this instability impediment.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Deciphering the chemical instability of sphaeropsidin A under physiological conditions - degradation studies and structural elucidation of the major metabolite. · full record | OpenQuestion